ストックスクリーナーアプリを入手
1.15
1.75%
0.01
前日終値:
$1.14
開ける：
$1.14
24時間の取引高:
120.24K
Relative Volume:
0.23
時価総額：
$71.21M
収益：
$248.00K
当期純損益:
$-113.22M
株価収益率:
-0.6245
EPS:
-1.8416
ネットキャッシュフロー:
$-98.81M
1週間 パフォーマンス:
-2.52%
1か月 パフォーマンス:
+0.87%
6か月 パフォーマンス:
-7.20%
1年 パフォーマンス:
-14.71%
1日の値動き範囲:
$1.14
$1.1599
1週間の範囲:
$1.12
$1.205
52週間の値動き範囲:
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
名前
Pliant Therapeutics Inc
セクター
電話
650-481-6770
住所
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.15 | 70.59M | 248.00K | -113.22M | -98.81M | -1.8416 |
VRTX
Vertex Pharmaceuticals Inc
|
450.65 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.75 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.14 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.91 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.41 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-03-04 | 再開されました | Cantor Fitzgerald | Neutral |
| 2025-03-04 | ダウングレード | Needham | Buy → Hold |
| 2025-03-03 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | ダウングレード | Stifel | Buy → Hold |
| 2025-02-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-02-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-02-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-02-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-05-18 | 開始されました | Canaccord Genuity | Buy |
| 2023-04-13 | 開始されました | Robert W. Baird | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-07 | 開始されました | JP Morgan | Overweight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Outperform |
| 2022-05-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-03 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-20 | 開始されました | BTIG Research | Buy |
| 2021-04-05 | 開始されました | Citigroup | Buy |
| 2020-06-29 | 開始されました | Citigroup | Buy |
| 2020-06-29 | 開始されました | Cowen | Outperform |
| 2020-06-29 | 開始されました | Needham | Buy |
| 2020-06-29 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Pliant Therapeutics Inc (PLRX) 最新ニュース
Pliant Therapeutics (PLRX) director receives 70,000 stock options at $1.14 - Stock Titan
Pliant Therapeutics (PLRX) director granted 70,000 options at $1.14 strike - Stock Titan
Pliant Therapeutics (PLRX) director receives 70,000-share stock option grant - Stock Titan
Pliant (NASDAQ: PLRX) director awarded 70,000 stock options at $1.14 - Stock Titan
PLIANT THERAPEUTICS (PLRX) director granted 70,000 stock options at $1.14 - Stock Titan
Director Darren Cline receives 70,000 PLRX stock options at $1.14 strike price - Stock Titan
Pliant Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Pliant Therapeutics (NASDAQ: PLRX) reports 2026 director, pay and auditor votes - Stock Titan
PLIANT THERAPEUTICS INC (PLRX) Stock Chart - ChartMill
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - The Manila Times
Primary Sclerosing Cholangitis Market is Projected to Boom by 2034 Owing to the Launch of Novel Therapies | DelveInsight - Barchart
Pliant Therapeutics (PLRX) Inches Higher: Consolidation Near Support Amid Biotech Sector VolatilityAccumulation Line - newsline.com
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest Gains, Biotech Sector Weakness PersistsNAAIM Leverage - The Legal Advocate
Pliant Therapeutics Rises $1.25 Ahead of ASCO Conference - Bez Kabli
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest Gains – Key Levels in FocusCumulative Volume - The Legal Advocate
Pliant Therapeutics (PLRX) Edges Higher as Stock Holds Above Key SupportNHNL Ratio - The Legal Advocate
Pliant Therapeutics (PLRX) Faces Selling Pressure, Testing Key Support at $1.15Revenue Growth Stocks - newsline.com
Pliant Therapeutics to present Phase 1b trial data of PLN-101095 at ASCO 2026. - Pluang
Pliant Therapeutics (PLRX) Bounces 2.5% as Biotech Tests Key ResistanceStock Idea Network - newser.com
Global oncology researchers to review FORTIFY data as Pliant Therapeutics joins ASCO meeting - Traders Union
Pliant Drug Aims to Break Cancer's Resistance to Immunotherapy - BriefGlance
Pliant Therapeutics (PLRX) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.32Crowd Entry Signals - newser.com
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical ... - Caledonian Record
Pliant Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
Phase 1 cancer trial pairs oral integrin inhibitor with pembrolizumab - Stock Titan
Pliant Therapeutics (PLRX) Stock: Consolidating at $1.20 — Next Move Ahead 2026-05-21Equity Put Call - Newser
Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Pliant Therapeutics (PLRX) Delivers Q1 2026 Beat — EPS $-0.32 vs $-0.36 ExpectedEPS Guidance Update - The Legal Advocate
Australian biotech advancing pulmonary program adds Pliant CEO as chair - Stock Titan
Pliant Therapeutics (PLRX) Stock Price, Quote, Charts & News - Invezz
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board – Company AnnouncementFT.com - Financial Times
TradingKey - TradingKey
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail
Number of shareholders of Pliant Therapeutics, Inc. – MUN:9PT - TradingView
CCORF Downgrades Pliant Therapeutics(PLRX.US) to Hold Rating, Maintains Target Price $3 - Moomoo
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $2 to $3 - Moomoo
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - markets.businessinsider.com
Pliant Therapeutics (PLRX) Advances Clinical Trials and Pipeline Development - GuruFocus
Pliant Therapeutics Q1 net loss narrows on lower expenses - TradingView
Pliant Therapeutics (NASDAQ: PLRX) cuts Q1 2026 net loss to $20M - Stock Titan
Pliant Therapeutics (PLRX) narrows Q1 2026 loss as PLN-101095 shows early responses - Stock Titan
Cancer pill from Pliant shows responses after checkpoint drugs fail - Stock Titan
Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
PLRX (Pliant Therapeutics) quarterly loss narrower than feared; shares tick up as pipeline hopes support sentiment.Margin Improvement - newser.com
The industry tailwinds powering Pliant Therapeutics (PLRX) growth (Smart Money Flows) 2026-05-08Call Spread Alert - newsline.com
Pliant CEO, CFO to join RBC healthcare fireside chat on May 19 - Stock Titan
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pliant Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen - MarketBeat
Pliant Therapeutics (PLRX) Initiates Key Clinical Trial for Canc - GuruFocus
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - Investing News Network
Pliant Therapeutics Inc (PLRX) 財務データ
収益
当期純利益
現金流量
EPS
Pliant Therapeutics Inc (PLRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cheung Lily | Chief Human Resource Officer |
Jan 20 '26 |
Sale |
1.28 |
7,534 |
9,644 |
44,847 |
| Coulie Bernard | President and CEO |
Jan 20 '26 |
Sale |
1.28 |
89,375 |
114,400 |
505,601 |
| Kuo Minnie | Chief Operating Officer |
Jan 20 '26 |
Sale |
1.28 |
6,917 |
8,854 |
37,806 |
1.61%
大文字化:
|
ボリューム (24 時間):